Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.11.6245

Effects of PTTG Down-regulation on Proliferation and Metastasis of the SCL-1 Cutaneous Squamous Cell Carcinoma Cell Line  

Xia, Yong-Hua (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
Li, Min (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
Fu, Dan-Dan (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
Xu, Su-Ling (Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University)
Li, Zhan-Guo (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
Liu, Dong (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
Tian, Zhong-Wei (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.11, 2013 , pp. 6245-6248 More about this Journal
Abstract
Aims: To study effects of down-regulation of pituitary tumor-transforming gene (PTTG) on proliferation and metastasis ability of the SCL-1 cutaneous squamous cell carcinoma (CSCC) cell line and explore related mechanisms. Methods: SCL-1 cells were divided into 3 groups (untreated, siRNA control and PTTG siRNA). Cell proliferation assays were performed using a CCK-8 kit and proliferation and metastasis ability were analyzed using Boyden chambers. In addition, expression of MMP-2 and MMP-9 was detected by r-time qPCR and Western blotting. Results: Down-regulation of PTTG could markedly inhibit cell proliferation in SCL-1 cells, compared to untreated and control siRNA groups (P < 0.05). Real-time qPCR demonstrated that expression levels of PTTG, MMP-2 and MMP-9 in the PTTG siRNA group were 0.8%, 23.2% and 21.3% of untreated levels. Western blotting revealed that expression of PTTG, MMP-2 and MMP-9 proteins in the PTTG siRNA group was obviously down-regulated. The numbers of migrating cells ($51.38{\pm}4.71$) in the PTTG siRNA group was obviously lower than that in untreated group ($131.33{\pm}6.12$) and the control siRNA group ($127.72{\pm}5.20$) (P < 0.05), suggesting that decrease of proliferation and metastasis ability mediated by PTTG knock-down may be closely correlated with down-regulation of MMP-2 and MMP-9 expression. Conclusion: Inhibition of PTTG expression may be a new target for therapy of CSCC.
Keywords
Cutaneous squamous cell carcinoma; pituitary tumor; transforming gene; proliferation; metastasis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Akino K, Akita S, Mizuguchi T, et al (2005). A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. J Surg Res, 129, 142-6.   DOI   ScienceOn
2 Bhave SL, Teknos TNPan Q (2011). Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gene Expr, 21, 143.   DOI
3 Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, et al (2003). Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg, 2003, 132-6.
4 Chen G, Li J, Li F, et al (2004). Inhibitory effects of anti-sense pttg on malignant phenotype of human ovarian carcinoma cell line sk-ov-3. J Huazhong Univ Sci Technolog Med Sci, 24, 369-72.(In Chinease)   DOI
5 Chollet A, Hohl D, Perrier P (2012). Risk of cutaneous squamous cell carcinomas: The role of clinical and pathological reports]. Rev Med Suisse, 8, 743.
6 Coussens LM, Tinkle CL, Hanahan D, et al (2000). Mmp-9 supplied by bone marrow.derived cells contributes to skin carcinogenesis. Cell, 103, 481-90.   DOI   ScienceOn
7 Fang J, Shing Y, Wiederschain D, et al (2000). Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Ncad Sci USA, 97, 3884-9.   DOI   ScienceOn
8 Franchi A, Santucci M, Masini E, et al (2002). Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer, 95, 1902-10.   DOI   ScienceOn
9 Gelse K, Poschl E, Aigner T (2003). Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev, 55, 1531-46.   DOI   ScienceOn
10 Geneva, Switzerland: World Health Organization. Too Much Fun in the Sun Dangerous; Press Release WHO/40; 3 August 1999. http://www.who.int/inf-pr-1999/en/pr99-40.html
11 Goh RY, Bova R, Fogarty GB (2012). Cutaneous squamous cell carcinoma metastatic to parotid-analysis of prognostic factors and treatment outcome. World J Surg Oncol, 10, 1-5.   DOI
12 Itoh Y, Nagase H (2002). Matrix metalloproteinases in cancer. Essays Biochem, 38, 21-36.   DOI
13 Jung CR, Yoo J, Jang YJ, et al (2006). Adenovirus-mediated transfer of sirna against pttg1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology, 43, 1042-52.   DOI   ScienceOn
14 Kakar SS, Malik MT (2006). Suppression of lung cancer with sirna targeting pttg. Int J Oncol, 29, 387.
15 Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141, 52-67.   DOI   ScienceOn
16 Mourouzis C, Boynton A, Grant J, et al (2009). Cutaneous head and neck sccs and risk of nodal metastasis.uk experience. J Craniomaxillofac Surg, 37, 443-7.   DOI   ScienceOn
17 Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-8.   DOI   ScienceOn
18 London CA, Sekhon HS, Arora V, et al (2003). A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther, 10, 823-32.   DOI   ScienceOn
19 Moore BA, Weber RS, Prieto V, et al (2005). Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope, 115, 1561-7.   DOI   ScienceOn
20 Ondruschka C, Buhtz P, Motsch C, et al (2002). Prognostic value of MMP-2,-9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract, 198, 509-15.   DOI   ScienceOn
21 Patel V, Ramesh A, Traicoff JL, et al (2005). Profiling egfr activity in head and neck squamous cell carcinoma by using a novel layered membrane western blot technology. Oral Oncol, 41, 503-8.   DOI   ScienceOn
22 Pei L, Melmed S (1997). Isolation and characterization of a pituitary tumor-transforming gene (pttg). Mol Endocrinol, 11, 433-41.   DOI
23 Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarker s and potential therapeutic targets in human cancer. J Clin Oncol, 27, 5287-97.   DOI   ScienceOn
24 Shibata Y, Haruki N, Kuwabara Y, et al (2002). Expression of pttg (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol, 32, 233-7.   DOI   ScienceOn
25 Zhang X, Horwitz GA, Heaney AP, et al (1999). Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab, 84, 761-7.   DOI
26 Solbach C, Roller M, Fellbaum C, et al (2004). PTTG mRNA expression in primary breast cancer: A prognostic marker for lymph node invasion and tumor recurrence. Breast, 13, 80-1.   DOI   ScienceOn
27 Urba W, Washington C, Nadiminti H (2012). Cancer of the Skin. In: Harrison's Principles of Internal Medicine (18th Edition) (Longo DL, Hause SL, Jameson JL and Loscalzo, eds.). McGraw-Hill Medical Publishing Division, New York.
28 Woodhouse EC, Chuaqui RF, Liotta LA (1997). General mechanisms of metastasis. Cancer, 80, 1529-37.   DOI